2017 Webinar: Controversy Regarding HCV Treatment and HCC Recurrence
Recorded On: 03/08/2017
- Registration Closed
This webinar will review this latest controversy regarding the increased risk of hepatocellular carcinoma recurrence in patients receiving direct acting antiviral agents for the treatment of HCV. Recent studies have suggested that HCC recurrence is increased in HCV patients receiving direct antiviral agents.
Michael D. Leise (Moderator)
Dr. Leise finished his internal medicine residency, chief residency, Gastroenterology and Transplant Hepatology fellowships at Mayo Clinic, Rochester. He is an Assistant Professor of Medicine with research interests in Hepatitis C, hepatic encephalopathy, and liver transplant outcomes.
Amit G. Singal
Dr. Singal is a Professor of Internal Medicine, Chief of Hepatology, and Medical Director of the Liver Tumor Program at UT Southwestern Medical Center in Dallas, TX. He has obtained state, DOD and NIH funding to examine the HCC care continuum, ranging from HCC prevention to screening and early detection to treatment and survivorship. Dr. Singal has published over 150 scientific papers regarding HCC screening and treatment. For his work, he has been awarded the David Bruton Professorship in Clinical Cancer Research and Blue Faery Award for Excellence in Liver Cancer Research.
